City of Hope’s Dr Tycel Phillips Discusses Promise of Glofitamab in Heavily Pretreated MCL
June 1st 2024Glofitamab is currently being investigated in a phase 1/2, multicenter, open-label, dose-escalation study as monotherapy and in combination with obinutuzumab, following 1-time fixed-dose pretreatment with obinutuzumab.
Watch
ASH Abstracts Showcase Effective Treatments for MM, CLL, FL
January 20th 2024Abstracts from the 65th American Society of Hematology (ASH) Annual Meeting and Exposition provided new insight into multiple treatments for patients with multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and follicular lymphoma (FL).
Read More
Pivotal Results Show Revumenib Holds Promise for Patients With KMT2Ar Acute Leukemia
December 12th 2023In AUGMENT-101, patients with R/R KMT2Ar acute leukemia had high overall response rates; despite being heavily pretreated, 40% were able to proceed to transplant and the KMT2Ar cohort was stopped early.
Read More
Joseph Alvarnas, MD, Discusses New CMS Drug Pricing Models, Impact for Blood Diseases
April 19th 2023CMS in February 2023 announced 3 new models for testing by the Center for Medicare & Medicaid Innovation—all of which “aim to lower the cost of drugs, promote accessibility to life-changing drug therapies, and improve quality of care.”
Read More
Dr Terrance Mayes and Dr Loretta Erhunmwunsee Discuss Leadership Roles for NCCN Forum on Equity
January 31st 2023Terrance Mayes, EdD, and Loretta Erhunmwunsee, MD, FACS, discuss their new roles as chair and vice-chair, respectively, of the National Comprehensive Cancer Network’s (NCCN) new Diversity, Equity, & Inclusion (DEI) Directors Forum.
Read More
PolaR-ICE Effective as Second-line Treatment in DLBCL, Bridge to Autologous Stem Cell Transplant
January 28th 2023Results presented during the 64th American Society of Hematology Annual Meeting and Exposition could offer an effective option for those with relapsed or refractory DLBCL, even as chimeric antigen receptor T-cell therapy becomes standard of care for many patients.
Read More